INDV — Indivior Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1625297 ·
Last close
$36.18
Market Cap
$4.27B
52W High
$42.81
52W Low
$32.41
ADV30
2,221,295
Next earnings
2026-08-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 343,000,000 | 293,000,000 | 159,000,000 | 122,000,000 | 1,233,000,000 | 222,000,000 | 1,440,000,000 |
| Mar 2026 | 317,000,000 | 277,000,000 | 137,000,000 | 89,000,000 | 1,197,000,000 | 175,000,000 | 1,341,000,000 |
| Dec 2025 | 358,000,000 | 291,000,000 | 83,000,000 | 102,000,000 | 1,201,000,000 | 195,000,000 | 1,300,000,000 |
| Sep 2025 | 314,000,000 | 231,000,000 | 44,000,000 | 42,000,000 | 1,416,000,000 | 445,000,000 | 1,623,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-41,000,000
Investing CF
$-70,000,000
Financing CF
$-176,000,000
CapEx
$-71,000,000
Dividends Paid
—
Buybacks
$-302,000,000
EPS Diluted TTM
$2.79
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-334,000,000
Inventory
$151,000,000
Receivables
$287,000,000
ST Investments
$0
EBIT TTM
$420,000,000
Pretax Income TTM
$393,000,000
Interest Exp TTM
$27,000,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,331,000,064
EBITDA
$576,000,000
Free Cash Flow
$86,500,000
Enterprise Value
$4,638,163,456
Total Cash
$222,000,000
Total Debt
$509,000,000
Shares Out
118,013,649
Trailing EPS
$2.79
Book Value
$-1.76
ROE
—
ROA
26.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,239,000,000 | 265,000,000 | 210,000,000 | 1,201,000,000 | 1,300,000,000 | — | -27,000,000 |
| Dec 2024 | 1,188,000,000 | 234,000,000 | 7,000,000 | 1,316,000,000 | 1,653,000,000 | — | 36,000,000 |
| Dec 2023 | 1,093,000,000 | 247,000,000 | -126,000,000 | 1,760,000,000 | 1,952,000,000 | — | -300,000,000 |
| Dec 2022 | 901,000,000 | 215,000,000 | -44,000,000 | 1,769,000,000 | 1,718,000,000 | — | -4,000,000 |
TTM Snapshot
Revenues TTM
$299,000,000
NetIncome TTM
$-97,000,000
OpCashFlow TTM
$0
Assets (Latest)
$1,758,000,000
Forward EPS
$4.88
Max Pain — expiry 2027-12-17
max pain strike: $35.00 · spot: $36.18 · call oi: 5,000 · put oi: 5,003Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.25B | $38.15 | — |
| GIKLY | Grifols SA | $4.31B | $5.10 | — |
| TNGX | Tango Therapeutics, Inc. | $4.13B | $24.51 | — |
| MANE | Veradermics, Inc | $4.11B | $98.46 | — |
| LEGN | Legend Biotech Corp | $4.07B | $20.94 | — |
News headlines (Yahoo Finance, 1h cache)
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan
2026-08-22 02:11 · Yahoo
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
2026-08-21 16:40 · Yahoo
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?
2026-08-21 14:48 · Yahoo
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
2026-08-04 16:18 · Yahoo
Indivior Q2 Earnings Call Highlights
2026-08-03 14:04 · Yahoo
Supernus jumps premarket on merger deal; GameStop drops
2026-08-03 12:22 · Yahoo
Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates
2026-08-03 11:45 · Yahoo
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
2026-08-03 10:31 · Yahoo
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
2026-08-03 10:30 · Yahoo
This Pharma Stock Eyes Entry As Opioid Addiction Specialist's Profits Surge 108%
2026-07-31 16:41 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.